{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T09:32:04Z","timestamp":1769160724162,"version":"3.49.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100008482","name":"Association of Public Health Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008482","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["U60HM000803"],"award-info":[{"award-number":["U60HM000803"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>In 2012, the California Department of Public Health began using pyrosequencing (PSQ) to detect mutations associated with resistance to isoniazid, rifampin, quinolones and injectable drugs in Mycobacterium tuberculosis complex. We evaluated the impact of the PSQ assay on the clinical management of tuberculosis (TB) in California.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>TB surveillance and laboratory data for specimens submitted 1 August 2012 through 31 December 2016 were analyzed to determine time to effective treatment initiation. A survey of clinicians was used to assess how PSQ results influenced clinical decision making.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 1957 specimens tested with PSQ, 52% were sediments and 46% were culture isolates, submitted a median of 8 and 35 days, respectively, after collection. Among 36 patients with multidrug-resistant (MDR) TB who had a sediment specimen submitted for PSQ, median time from specimen collection to MDR-TB treatment initiation was 12 days vs 51 days when PSQ was not used. Completed surveys were returned for 303 patients, 177 of whom reported a treatment change; 75 (42%) of clinicians reported PSQ as a reason for change. Twenty-one patients either had an MDR-TB risk factor and a smear-positive sputum specimen, but had PSQ performed on a culture isolate (9\/36 [25%]); or did not have PSQ used for MDR-TB diagnosis (12\/38 [32%]) and thus had an opportunity for earlier MDR-TB diagnosis with PSQ on sediment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Patients with MDR-TB initiated effective treatment 5 weeks earlier when PSQ was used compared to those without PSQ. Survey data suggest clinicians use PSQ to devise effective TB drug regimens. To maximize the benefit of PSQ, earlier submission of specimens should be prioritized.<\/jats:p><\/jats:sec>","DOI":"10.1093\/cid\/ciy937","type":"journal-article","created":{"date-parts":[[2018,10,30]],"date-time":"2018-10-30T20:14:33Z","timestamp":1540930473000},"page":"668-675","source":"Crossref","is-referenced-by-count":6,"title":["Evaluation of the Impact of a Sequencing Assay for Detection of Drug Resistance on the Clinical Management of Tuberculosis"],"prefix":"10.1093","volume":"69","author":[{"given":"Phil","family":"Lowenthal","sequence":"first","affiliation":[{"name":"Tuberculosis Control Branch, Division of Communicable Disease, Center for Infectious Disease, California Department of Public Health, Richmond"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shou-Yean Grace","family":"Lin","sequence":"additional","affiliation":[{"name":"Microbial Disease Laboratory, Division of Communicable Disease, Center for Infectious Disease, California Department of Public Health, Richmond"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ed","family":"Desmond","sequence":"additional","affiliation":[{"name":"Microbial Disease Laboratory, Division of Communicable Disease, Center for Infectious Disease, California Department of Public Health, Richmond"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neha","family":"Shah","sequence":"additional","affiliation":[{"name":"Tuberculosis Control Branch, Division of Communicable Disease, Center for Infectious Disease, California Department of Public Health, Richmond"},{"name":"Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Flood","sequence":"additional","affiliation":[{"name":"Tuberculosis Control Branch, Division of Communicable Disease, Center for Infectious Disease, California Department of Public Health, Richmond"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pennan M","family":"Barry","sequence":"additional","affiliation":[{"name":"Tuberculosis Control Branch, Division of Communicable Disease, Center for Infectious Disease, California Department of Public Health, Richmond"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,11,1]]},"reference":[{"key":"2019080101003540400_CIT0001","volume-title":"Global tuberculosis report 2018","author":"World Health Organization"},{"key":"2019080101003540400_CIT0002","volume-title":"Report on tuberculosis in California, 2017","author":"Tuberculosis Control Branch","year":"2018"},{"key":"2019080101003540400_CIT0003","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5588\/pha.17.0091","article-title":"The California Multidrug-Resistant Tuberculosis Consult Service: a partnership of state and local programs","volume":"8","author":"Shah","year":"2018","journal-title":"Public Health Action"},{"key":"2019080101003540400_CIT0004","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1128\/JCM.02741-12","article-title":"Rifampin resistance missed in automated liquid culture system for Mycobacterium tuberculosis isolates with specific rpoB mutations","volume":"51","author":"Rigouts","year":"2013","journal-title":"J Clin Microbiol"},{"key":"2019080101003540400_CIT0005","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1093\/clinchem\/47.8.1553","article-title":"Molecular detection of Mycobacterium tuberculosis: impact on patient care","volume":"47","author":"Kaul","year":"2001","journal-title":"Clin Chem"},{"key":"2019080101003540400_CIT0006","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s12879-016-1524-0","article-title":"The effect of early versus late treatment initiation after diagnosis on the outcomes of patients treated for multidrug-resistant tuberculosis: a systematic review","volume":"16","author":"Harris","year":"2016","journal-title":"BMC Infect Dis"},{"key":"2019080101003540400_CIT0007","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1128\/JCM.01889-10","article-title":"Evaluation of two molecular assays for rapid detection of Mycobacterium tuberculosis resistance to fluoroquinolones in high-tuberculosis and -multidrug-resistance settings","volume":"49","author":"Kontsevaya","year":"2011","journal-title":"J Clin Microbiol"},{"key":"2019080101003540400_CIT0008","author":"World Health Organization","year":"2008"},{"key":"2019080101003540400_CIT0009","volume-title":"Report of expert consultations on rapid molecular testing to detect drug-resistant tuberculosis in the United States","author":"Centers for Disease Control and Prevention","year":"2016"},{"key":"2019080101003540400_CIT0010","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1128\/JCM.01821-13","article-title":"Pyrosequencing for rapid detection of extensively drug-resistant Mycobacterium tuberculosis in clinical isolates and clinical specimens","volume":"52","author":"Lin","year":"2014","journal-title":"J Clin Microbiol"},{"key":"2019080101003540400_CIT0011","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.diagmicrobio.2015.07.004","article-title":"Pyrosequencing for rapid detection of Mycobacterium tuberculosis second-line drugs and ethambutol resistance","volume":"83","author":"Lacoma","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2019080101003540400_CIT0012","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1128\/JCM.42.9.4204-4208.2004","article-title":"Rapid detection of isoniazid and rifampin resistance mutations in Mycobacterium tuberculosis complex from cultures or smear-positive sputa by use of molecular beacons","volume":"42","author":"Lin","year":"2004","journal-title":"J Clin Microbiol"},{"key":"2019080101003540400_CIT0013","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.diagmicrobio.2016.01.019","article-title":"Rifabutin and rifampin resistance levels and associated rpoB mutations in clinical isolates of Mycobacterium tuberculosis complex","volume":"85","author":"Berrada","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2019080101003540400_CIT0014","doi-asserted-by":"crossref","first-page":"e0136861","DOI":"10.1371\/journal.pone.0136861","article-title":"Performance comparison of three rapid tests for the diagnosis of drug-resistant tuberculosis","volume":"10","author":"Catanzaro","year":"2015","journal-title":"PLoS One"},{"key":"2019080101003540400_CIT0015","author":"California Department of Public Health","year":"2014"},{"key":"2019080101003540400_CIT0016","author":"World Health Organization","year":"2011"},{"key":"2019080101003540400_CIT0017","doi-asserted-by":"crossref","first-page":"3779","DOI":"10.1128\/JCM.01236-10","article-title":"Rapid drug susceptibility testing with a molecular beacon assay is associated with earlier diagnosis and treatment of multidrug-resistant tuberculosis in California","volume":"48","author":"Banerjee","year":"2010","journal-title":"J Clin Microbiol"},{"key":"2019080101003540400_CIT0018","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/1741-7015-11-190","article-title":"Rapid diagnostics of tuberculosis and drug resistance in the industrialized world: clinical and public health benefits and barriers to implementation","volume":"11","author":"Drobniewski","year":"2013","journal-title":"BMC Med"},{"key":"2019080101003540400_CIT0019","first-page":"838","article-title":"Timely diagnosis of MDR-TB under program conditions: is rapid drug susceptibility testing sufficient","volume":"10","author":"Yagui","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"key":"2019080101003540400_CIT0020","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1128\/JCM.01239-11","article-title":"Pyrosequencing for rapid molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis strains and clinical specimens","volume":"49","author":"Garc\u00eda-Sierra","year":"2011","journal-title":"J Clin Microbiol"},{"key":"2019080101003540400_CIT0021","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1128\/JCM.06664-11","article-title":"Detection of first- and second-line drug resistance in Mycobacterium tuberculosis clinical isolates by pyrosequencing","volume":"50","author":"Engstr\u00f6m","year":"2012","journal-title":"J Clin Microbiol"},{"key":"2019080101003540400_CIT0022","doi-asserted-by":"crossref","first-page":"e686","DOI":"10.1136\/bmj.e686","article-title":"Assessing the value of diagnostic tests: a framework for designing and evaluating trials","volume":"344","author":"Ferrante di Ruffano","year":"2012","journal-title":"BMJ"},{"key":"2019080101003540400_CIT0023","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.1093\/infdis\/jis188","article-title":"Which new diagnostics for tuberculosis, and when","volume":"205(Suppl 2)","author":"Cobelens","year":"2012","journal-title":"J Infect Dis"},{"key":"2019080101003540400_CIT0024","doi-asserted-by":"crossref","first-page":"860","DOI":"10.5588\/ijtld.12.0180","article-title":"Diagnosis of tuberculosis and drug resistance: what can new tools bring us","volume":"16","author":"Drobniewski","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"2019080101003540400_CIT0025","doi-asserted-by":"crossref","first-page":"S1187","DOI":"10.1093\/infdis\/jir412","article-title":"Evaluation of tuberculosis diagnostics: establishing an evidence base around the public health impact","volume":"204(Suppl 4)","author":"Lessells","year":"2011","journal-title":"J Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/69\/4\/668\/29022145\/ciy937.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,14]],"date-time":"2020-11-14T10:15:36Z","timestamp":1605348936000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/69\/4\/668\/5154873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,1]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,11,1]]},"published-print":{"date-parts":[[2019,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciy937","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,8,15]]},"published":{"date-parts":[[2018,11,1]]}}}